Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model

BACKGROUND: Some patients with cancer treated with anticancer monoclonal antibodies (mAbs) develop antidrug antibodies (ADAs) that recognize and bind the therapeutic antibody. This response may neutralize the therapeutic mAb, interfere with mAb effector function or cause toxicities. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Baniel, Claire C, Sumiec, Elizabeth G, Hank, Jacquelyn A, Bates, Amber M, Erbe, Amy K, Pieper, Alexander A, Hoefges, Anna G, Patel, Ravi B, Rakhmilevich, Alexander L, Morris, Zachary S, Sondel, Paul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594540/
https://www.ncbi.nlm.nih.gov/pubmed/33115944
http://dx.doi.org/10.1136/jitc-2020-001262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594540/
https://www.ncbi.nlm.nih.gov/pubmed/33115944
http://dx.doi.org/10.1136/jitc-2020-001262

Ejemplares similares